EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Intermediate AMD: If you have intermediate AMD in one or both eyes, AREDS 2 supplements may help prevent it from turning into late-stage AMD, which causes significant vision loss. Late AMD in One Eye: ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Opthea Ltd shares have reached a remarkable 52-week high, touching $5.48 amidst a period of significant growth. With a market capitalization of nearly $798 million, the company has caught analysts' ...

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as ... Read More The ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...